Drug Patents Expiring in 2025

1. Abilify patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(a month from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Aug 27, 2011
New Indication(I-616) Nov 19, 2012
New Indication(I-633) Feb 16, 2014
M(M-137) Jun 09, 2017
New Indication(I-700) Dec 12, 2017
Orphan Drug Exclusivity(ODE) Dec 12, 2021
Orphan Drug Exclusivity(ODE-80) Dec 12, 2021

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 20 September, 2006

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Asimtufii patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA Methods for administering aripiprazole
Mar, 2025

(2 months from now)




Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: Use of aripiprazole in extended release injectable suspension

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Abilify Maintena Kit patent expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

4. Abraxane patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820788

(Pediatric)

BRISTOL-MYERS Compositions and methods of delivery of pharmacological agents
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-658) Oct 11, 2015
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
M(M-14) Dec 06, 2022
Pediatric Exclusivity(PED) Jun 06, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: NA

Dosage: POWDER

More Information on Dosage

ABRAXANE family patents

Family Patents

5. Acetadote patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(8 months from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(8 months from now)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE

More Information on Dosage

ACETADOTE family patents

Family Patents

6. Admelog Solostar patent expiration

ADMELOG SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI-AVENTIS US Pen-type injector
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 11, 2020

Drugs and Companies using INSULIN LISPRO ingredient

Market Authorisation Date: 11 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ADMELOG SOLOSTAR family patents

Family Patents

7. Adrenaclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166334 IMPAX Medicine injection apparatuses
Jan, 2025

(a month from now)

US10166344 IMPAX Injection needle assembly
Jan, 2025

(a month from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

ADRENACLICK family patents

Family Patents

8. Advair Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Jan, 2025

(19 days from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(6 months from now)




Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

ADVAIR HFA family patents

Family Patents

9. Aemcolo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(4 months from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(4 months from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(4 months from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2023
Generating Antibiotic Incentives Now(GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE

More Information on Dosage

AEMCOLO family patents

Family Patents

10. Afinitor patent expiration

AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment
Nov, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-638) May 05, 2014
New Indication(I-650) Apr 26, 2015
New Indication(I-655) Jul 20, 2015
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE) Apr 26, 2019
Orphan Drug Exclusivity(ODE-11) May 05, 2018
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 09 July, 2010

Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib

Dosage: TABLET

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

11. Airduo Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987229

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 months from now)

US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

12. Airduo Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 months from now)

US9987229

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

13. Aklief patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 5 days from now)

US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 5 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 04, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 05 October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor

Dosage: CREAM

More Information on Dosage

AKLIEF family patents

Family Patents

14. Amitiza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-670) Apr 19, 2016
M(M-225) Apr 26, 2021

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 29 April, 2008

Treatment: Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome

Dosage: CAPSULE

More Information on Dosage

AMITIZA family patents

Family Patents

15. Amondys 45 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48960 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2026
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping

Dosage: SOLUTION

More Information on Dosage

AMONDYS 45 family patents

Family Patents

16. Ampyra patent expiration

AMPYRA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8663685 MERZ PHARMS Sustained release aminopyridine composition
Jan, 2025

(a month from now)

US8440703 MERZ PHARMS Methods of using sustained release aminopyridine compositions
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2015
Orphan Drug Exclusivity(ODE) Jan 22, 2017

Drugs and Companies using DALFAMPRIDINE ingredient

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

AMPYRA family patents

Family Patents

17. Amrix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Feb, 2025

(2 months from now)




Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 February, 2007

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of AMRIX before it's drug patent expiration?
More Information on Dosage

AMRIX family patents

Family Patents

18. Anoro Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(4 months from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(4 months from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(7 months from now)

US7439393

(Pediatric)

GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

19. Antara (micronized) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate
Apr, 2025

(4 months from now)




Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia

Dosage: CAPSULE

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

20. Apidra Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents

21. Aptiom patent expiration

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702536 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(4 months from now)

US10695354 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(4 months from now)

US11364247 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(4 months from now)

US10675287 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures

Dosage: TABLET

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

22. Arcapta Neohaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016

Drugs and Companies using INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

23. Arikayce Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718189 INSMED INC Sustained release of antiinfectives
Jun, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

24. Armonair Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

25. Armonair Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 months from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

26. Astepro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MEDA PHARMS Compositions comprising azelastine and methods of use thereof
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 31, 2012
M(M-129) Aug 30, 2016
New Patient Population(NPP) Feb 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 August, 2009

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

27. Astepro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(11 months from now)

US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 31, 2012
M(M-129) Aug 30, 2016
New Patient Population(NPP) Feb 20, 2018

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

28. Astepro Allergy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(11 months from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(11 months from now)




Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents

29. Auvi-q patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(30 days from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(3 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(4 months from now)

US9149579 KALEO INC Devices, systems and methods for medicament delivery
Jul, 2025

(7 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: Method of treating allergic reaction via injection

Dosage: SOLUTION

More Information on Dosage

AUVI-Q family patents

Family Patents

30. Baxdela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(9 months from now)

US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
New Indication(I-815) Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: TABLET; POWDER

More Information on Dosage

BAXDELA family patents

Family Patents

31. Belviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8697686 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 4 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980881 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 4 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Method for chronic weight management by controlling weight gain

Dosage: TABLET

More Information on Dosage

BELVIQ family patents

Family Patents

32. Belviq Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8697686 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 4 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980881 EISAI INC Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
Dec, 2025

(1 year, 4 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Method for chronic weight management by controlling weight gain

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

BELVIQ XR family patents

Family Patents

33. Bepreve patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784789 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Jan, 2025

(28 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 08, 2014

Drugs and Companies using BEPOTASTINE BESILATE ingredient

NCE-1 date: 08 September, 2013

Market Authorisation Date: 08 September, 2009

Treatment: NA

Dosage: SOLUTION/DROPS

More Information on Dosage

BEPREVE family patents

Family Patents

34. Biktarvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 18, 2022
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
M(M-82) Feb 24, 2024
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
New Indication(I-942) Feb 23, 2027
M(M-305) Apr 24, 2027
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: TABLET

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

35. Bosulif patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(11 months from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2017
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
New Indication(I-923) Sep 26, 2026
New Product(NP) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

NCE-1 date: 26 March, 2026

Market Authorisation Date: 04 September, 2012

Treatment: A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy

Dosage: TABLET; CAPSULE

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

36. Breo Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7439393

(Pediatric)

GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 30, 2018
New Indication(I-708) Apr 30, 2018
New Chemical Entity Exclusivity(NCE) May 10, 2018
M(M-202) May 15, 2020
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: Maintenance treatment of asthma in patients aged 5 years and older. recommended dosages: breo 100/25 or 200/25 ages 18 years and older; Breo 100/25 ages 12-17 years, and breo 50/25, ages 5-11 years

Dosage: POWDER

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

37. Brilinta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2016
New Indication(I-714) Sep 03, 2018
New Strength(NS) Sep 03, 2018
New Indication(I-851) May 28, 2023
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

38. Brisdelle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 28, 2016

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage

BRISDELLE family patents

Family Patents

39. Brixadi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545832 BRAEBURN Lipid depot formulations
Jun, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

BRIXADI family patents

Family Patents

40. Bydureon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 14 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON family patents

Family Patents

41. Bydureon Bcise patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 14 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

42. Bydureon Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 14 days from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON PEN family patents

Family Patents

43. Cabenuva Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents

44. Children's Astepro Allergy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(11 months from now)

US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(11 months from now)




Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED

How can I launch a generic of CHILDREN'S ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ASTEPRO ALLERGY family patents

Family Patents

45. Chlorhexidine Gluconate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7717889 SAGE PRODS Disinfectant delivery system and method of providing alcohol free disinfection
Feb, 2025

(2 months from now)




Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

Family Patents

46. Ciprodex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846650 SANDOZ Method of treating middle ear infections
Jun, 2025

(5 months from now)




Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media

Dosage: SUSPENSION/DROPS

How can I launch a generic of CIPRODEX before it's drug patent expiration?
More Information on Dosage

CIPRODEX family patents

Family Patents

47. Combivent Respimat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED

More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

48. Combogesic patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532036 AFT PHARMS US Combination composition
Sep, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 01, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient

Market Authorisation Date: 01 March, 2023

Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration

Dosage: TABLET

More Information on Dosage

COMBOGESIC family patents

Family Patents

49. Complera patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Dec 13, 2016

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

50. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7375111 NALPROPION Compositions for affecting weight loss
Mar, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

CONTRAVE family patents

Family Patents

51. Coreg Cr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101209 WAYLIS THERAP Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Sep, 2025

(8 months from now)




Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

COREG CR family patents

Family Patents

52. Cresemba patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(10 months from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
Orphan Drug Exclusivity(ODE) Mar 06, 2022
ODE*(ODE*) Mar 06, 2022
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Patient Population(NPP) Dec 08, 2026
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE-453) Dec 08, 2030
Orphan Drug Exclusivity(ODE-454) Dec 08, 2030
Orphan Drug Exclusivity(ODE-458) Dec 08, 2030
Orphan Drug Exclusivity(ODE-459) Dec 08, 2030
Pediatric Exclusivity(PED) Jun 08, 2031

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 22 November, 2022

Treatment: NA

Dosage: CAPSULE; POWDER

More Information on Dosage

CRESEMBA family patents

Family Patents

53. Daytrana patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers
Oct, 2025

(9 months from now)

US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(9 months from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 29, 2013

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 06 April, 2006

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE

More Information on Dosage

DAYTRANA family patents

Family Patents

54. Defencath patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696182 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2028
Generating Antibiotic Incentives Now(GAIN) Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 15 November, 2032

Market Authorisation Date: 15 November, 2023

Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter

Dosage: SOLUTION

More Information on Dosage

DEFENCATH family patents

Family Patents

55. Descovy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 28, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Indication(I-812) Oct 03, 2022
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: NA

Dosage: TABLET

More Information on Dosage

DESCOVY family patents

Family Patents

56. Differin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579377 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Mar 17, 2013
RTO(RTO) Jul 08, 2019

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: Topical treatment of acne vulgaris

Dosage: GEL

More Information on Dosage

DIFFERIN family patents

Family Patents

57. Diprivan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(5 months from now)




Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents

58. Dojolvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 30, 2025
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID

More Information on Dosage

DOJOLVI family patents

Family Patents

59. Duaklir Pressair patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46417 COVIS Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED

More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

60. Durysta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673341 ABBVIE Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT

More Information on Dosage

DURYSTA family patents

Family Patents

61. Duvyzat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7329689 ITALFARMACO SPA Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
Jan, 2025

(30 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2029
Orphan Drug Exclusivity(ODE-473) Mar 21, 2031

Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient

NCE-1 date: 21 March, 2028

Market Authorisation Date: 21 March, 2024

Treatment: NA

Dosage: SUSPENSION

More Information on Dosage

DUVYZAT family patents

Family Patents

62. Duzallo patent expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(8 months from now)




Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

DUZALLO family patents

Family Patents

63. Edarbi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(22 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

More Information on Dosage

EDARBI family patents

Family Patents

64. Edarbyclor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(22 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 20, 2014
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

65. Edurant patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125879

(Pediatric)

JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Aug 26, 2018
M(M-223) Feb 01, 2021

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy

Dosage: TABLET

More Information on Dosage

EDURANT family patents

Family Patents

66. Edurant Ped patent expiration

EDURANT PED's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(4 months from now)




Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 March, 2024

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...

Dosage: TABLET, FOR SUSPENSION

More Information on Dosage

EDURANT PED family patents

Family Patents

67. Elelyso patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8790641 PFIZER Production of high mannose proteins in plant culture and therapeutic uses thereof
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 01, 2017
New Patient Population(NPP) Aug 27, 2017

Drugs and Companies using TALIGLUCERASE ALFA ingredient

NCE-1 date: 01 May, 2016

Market Authorisation Date: 01 May, 2012

Treatment: A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide.

Dosage: POWDER

More Information on Dosage

ELELYSO family patents

Family Patents

68. Embeda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685444 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(6 months from now)

US8685443 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

EMBEDA family patents

Family Patents

69. Entresto patent expiration

ENTRESTO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(30 days from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

ENTRESTO family patents

Family Patents

70. Entresto Sprinkle patent expiration

ENTRESTO SPRINKLE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS Methods of treatment and pharmaceutical composition
Jan, 2025

(30 days from now)




Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: NA

Dosage: CAPSULE, PELLETS

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

71. Epanova patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form
Feb, 2025

(a month from now)

US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(a month from now)

US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 05, 2019

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

NCE-1 date: 05 May, 2018

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia

Dosage: CAPSULE

More Information on Dosage

EPANOVA family patents

Family Patents

72. Epiduo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 08, 2011
New Patient Population(NPP) Feb 01, 2016

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: NA

Dosage: GEL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

73. Epipen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(8 months from now)

US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(8 months from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(8 months from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(8 months from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(8 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 03 August, 1995

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of EPIPEN before it's drug patent expiration?
More Information on Dosage

EPIPEN family patents

Family Patents

74. Epipen Jr. patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(8 months from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(8 months from now)

US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(8 months from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(8 months from now)

US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(8 months from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 03 August, 1995

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

EPIPEN JR. family patents

Family Patents

75. Erivedge patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 30, 2017

Drugs and Companies using VISMODEGIB ingredient

NCE-1 date: 31 January, 2016

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat basal cell carcinoma

Dosage: CAPSULE

More Information on Dosage

ERIVEDGE family patents

Family Patents

76. Evzio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(30 days from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(3 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(4 months from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

EVZIO family patents

Family Patents

77. Evzio (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(30 days from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(3 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(4 months from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

78. Exondys 51 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486907 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE) Sep 19, 2023
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)-(iii) in patients having a confirmed mutation of the dmd ge...

Dosage: SOLUTION

More Information on Dosage

EXONDYS 51 family patents

Family Patents

79. Exxua patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7538116 FABRE KRAMER Treatment of sexual disorders
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2028

Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient

NCE-1 date: 23 September, 2027

Market Authorisation Date: 22 September, 2023

Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

EXXUA family patents

Family Patents

80. Fanapt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138432 VANDA PHARMS INC Methods for the administration of iloperidone
Sep, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2014
M(M-180) May 26, 2019
New Indication(I-939) Apr 02, 2027

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine

Dosage: TABLET

More Information on Dosage

FANAPT family patents

Family Patents

81. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 14 days from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

82. Femtrace patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Oct, 2025

(9 months from now)




Drugs and Companies using ESTRADIOL ACETATE ingredient

Market Authorisation Date: 20 August, 2004

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET

More Information on Dosage

FEMTRACE family patents

Family Patents

83. Fiasp Flextouch patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 29, 2020
New Patient Population(NPP) Dec 19, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

84. Filsuvez patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828444 CHIESI Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2028
Orphan Drug Exclusivity(ODE-460) Dec 18, 2030

Drugs and Companies using BIRCH TRITERPENES ingredient

NCE-1 date: 19 December, 2027

Market Authorisation Date: 18 December, 2023

Treatment: NA

Dosage: GEL

More Information on Dosage

FILSUVEZ family patents

Family Patents

85. Flovent Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Jan, 2025

(19 days from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(6 months from now)




Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage

FLOVENT HFA family patents

Family Patents

86. Folotyn patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622470 ACROTECH BIOPHARMA Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(5 months from now)

US8299078 ACROTECH BIOPHARMA Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 24, 2014
Orphan Drug Exclusivity(ODE) Sep 24, 2016

Drugs and Companies using PRALATREXATE ingredient

NCE-1 date: 24 September, 2013

Market Authorisation Date: 24 September, 2009

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION

How can I launch a generic of FOLOTYN before it's drug patent expiration?
More Information on Dosage

FOLOTYN family patents

Family Patents

87. Forteo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7517334 LILLY Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
Mar, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-602) Jul 22, 2012
M(M-302) Nov 16, 2023

Drugs and Companies using TERIPARATIDE ingredient

Market Authorisation Date: 25 June, 2008

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

FORTEO family patents

Family Patents

88. Fotivda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 10 March, 2025

Market Authorisation Date: 10 March, 2021

Treatment: A method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular end...

Dosage: CAPSULE

More Information on Dosage

FOTIVDA family patents

Family Patents

89. Fycompa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6949571 CATALYST PHARMS 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 22, 2017
New Indication(I-710) Jun 19, 2018

Drugs and Companies using PERAMPANEL ingredient

NCE-1 date: 22 October, 2016

Market Authorisation Date: 22 October, 2012

Treatment: Treatment of epilepsy

Dosage: TABLET; SUSPENSION

More Information on Dosage

FYCOMPA family patents

Family Patents

90. Gattex Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987335 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9545434 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US7847061 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9572867 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9974835 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9968658 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9981014 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9545435 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9060992 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9987334 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9993528 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9592273 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9592274 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9981016 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9974837 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9539310 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9555079 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9968655 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)

US9968656 TAKEDA PHARMS USA Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2017
Orphan Drug Exclusivity(ODE) Dec 21, 2019
Orphan Drug Exclusivity(ODE-37) Dec 21, 2019
Pediatric Exclusivity(PED) Jun 21, 2020
Orphan Drug Exclusivity(ODE-240) May 16, 2026

Drugs and Companies using TEDUGLUTIDE ingredient

NCE-1 date: 22 June, 2019

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER

More Information on Dosage

GATTEX KIT family patents

Family Patents

91. Genosyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956373 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US11291793 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US9522249 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US8609028 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US11554241 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US8226916 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US10124142 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US8821801 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US11383059 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(8 months from now)

US10814092 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2025

(10 months from now)




Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS

More Information on Dosage

GENOSYL family patents

Family Patents

92. Genvoya patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Dosing Schedule(D-173) Dec 10, 2021

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

GENVOYA family patents

Family Patents

93. Givlaari patent expiration

GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

GIVLAARI family patents

Family Patents

94. Glumetza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7780987 SANTARUS INC Controlled release dosage forms
Mar, 2025

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323692 SANTARUS INC Controlled release dosage forms
Mar, 2025

(3 months from now)




Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 03 June, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

GLUMETZA family patents

Family Patents

95. Glyxambi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 30, 2018
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

96. Gocovri patent expiration

Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895614 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895617 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895616 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8796337 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8889740 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895618 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895615 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-769) Aug 24, 2020
New Product(NP) Aug 24, 2020
Orphan Drug Exclusivity(ODE) Aug 24, 2024
Orphan Drug Exclusivity(ODE-153) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

GOCOVRI family patents

Family Patents

97. Horizant patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6818787 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034 AZURITY Crystalline form of γ-aminobutyric acid analog
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-652) Jun 06, 2015
New Chemical Entity Exclusivity(NCE) Apr 06, 2016
Orphan Drug Exclusivity(ODE) Jun 06, 2019
Orphan Drug Exclusivity(ODE-25) Jun 06, 2019

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: Management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage

HORIZANT family patents

Family Patents

98. Hysingla Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844865 PURDUE PHARMA LP Abuse-proofed oral dosage form
Feb, 2025

(a month from now)




Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage

HYSINGLA ER family patents

Family Patents

99. Incivek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 23, 2016

Drugs and Companies using TELAPREVIR ingredient

NCE-1 date: 24 May, 2015

Market Authorisation Date: 23 May, 2011

Treatment: NA

Dosage: TABLET

More Information on Dosage

INCIVEK family patents

Family Patents

100. Incruse Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(4 months from now)

US8183257 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Jul, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-172) Feb 24, 2019
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 30 April, 2014

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER

More Information on Dosage

INCRUSE ELLIPTA family patents

Family Patents

101. Injectafer patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 25, 2016
New Strength(NS) Apr 28, 2024
New Patient Population(NPP) Nov 19, 2024
New Indication(I-915) May 31, 2026

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 28 April, 2021

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

INJECTAFER family patents

Family Patents

102. Inlyta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6534524

(Pediatric)

PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

Drugs and Companies using AXITINIB ingredient

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

103. Intermezzo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252809 PURDUE PHARMA Compositions for treating insomnia
Feb, 2025

(2 months from now)

US7682628 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 23, 2014

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 23 November, 2011

Treatment: Method for treating insomnia

Dosage: TABLET

How can I launch a generic of INTERMEZZO before it's drug patent expiration?
More Information on Dosage

INTERMEZZO family patents

Family Patents

104. Invokamet patent expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET

More Information on Dosage

INVOKAMET family patents

Family Patents

105. Invokamet Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

106. Invokana patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-733) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Indication(I-809) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET

More Information on Dosage

INVOKANA family patents

Family Patents

107. Ixempra Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237

(Pediatric)

R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2012
Pediatric Exclusivity(PED) Apr 18, 2015
M(M-61) Oct 18, 2014

Drugs and Companies using IXABEPILONE ingredient

NCE-1 date: 18 April, 2014

Market Authorisation Date: 16 October, 2007

Treatment: NA

Dosage: INJECTABLE

How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

Family Patents

108. Izervay patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7538211 ASTELLAS Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(a month from now)

US9617546 ASTELLAS Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(a month from now)

US7803931 ASTELLAS Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(a month from now)

US10947544 ASTELLAS Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(a month from now)

US7579456 ASTELLAS Aptamer therapeutics useful in the treatment of complement-related disorders
Feb, 2025

(a month from now)




Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient

Market Authorisation Date: 04 August, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye

Dosage: SOLUTION

More Information on Dosage

IZERVAY family patents

Family Patents

109. Jentadueto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 30, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-146) Jul 30, 2017
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage

JENTADUETO family patents

Family Patents

110. Jentadueto Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents

111. Jevtana Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2015
M(M-201) May 17, 2020
M(M-209) Sep 14, 2020
Pediatric Exclusivity(PED) Nov 17, 2020
M(M-128) Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

NCE-1 date: 18 November, 2019

Market Authorisation Date: 17 June, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage

JEVTANA KIT family patents

Family Patents

112. Juluca patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Combination(NC) Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

113. Juxtapid patent expiration

JUXTAPID IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861622 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 months from now)

US9433617 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 months from now)

US10555938 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(2 months from now)

US8618135 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(2 months from now)

US9265758 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 months from now)

US10016404 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(2 months from now)

US9364470 CHIESI Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2017
Orphan Drug Exclusivity(ODE) Dec 21, 2019
Orphan Drug Exclusivity(ODE-36) Dec 21, 2019

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

NCE-1 date: 21 December, 2016

Market Authorisation Date: 21 December, 2012

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regime...

Dosage: CAPSULE

More Information on Dosage

JUXTAPID family patents

Family Patents

114. Kaletra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)

US8691878

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)

US8268349

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)

US8309613

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-124) Apr 27, 2013

Drugs and Companies using LOPINAVIR; RITONAVIR ingredient

Market Authorisation Date: 09 November, 2007

Treatment: NA

Dosage: TABLET

More Information on Dosage

KALETRA family patents

Family Patents

115. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 03 May, 2023

Treatment: Treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 1 month to <4 months who has at least one cftr mutation responsive to ivacaftor based on clinical and/or in vi...

Dosage: GRANULE

More Information on Dosage

KALYDECO family patents

Family Patents

116. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 20 May, 2019

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in ...

Dosage: TABLET

More Information on Dosage

KALYDECO family patents

Family Patents

117. Kazano patent expiration

Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 25, 2016
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019
M(M-300) Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET

More Information on Dosage

KAZANO family patents

Family Patents

118. Klisyri patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(1 year, 12 days from now)

US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(1 year, 12 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2025
New Dosing Schedule(D-192) Jun 07, 2027

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 14 December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: NA

Dosage: OINTMENT

More Information on Dosage

KLISYRI family patents

Family Patents

119. Kombiglyze Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(6 months from now)

US9339472 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 05 November, 2010

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents

120. Koselugo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(2 months from now)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 10 April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

KOSELUGO family patents

Family Patents

121. Kuvan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433624

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(4 months from now)

US7566714

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(4 months from now)

USRE43797

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin
May, 2025

(4 months from now)

US7612073

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
May, 2025

(4 months from now)

US8067416

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(4 months from now)

US8318745

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
May, 2025

(4 months from now)

US7727987

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
May, 2025

(4 months from now)

US7947681

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
May, 2025

(4 months from now)

US7566462 BIOMARIN PHARM Stable tablet formulation
Nov, 2025

(10 months from now)

US8003126 BIOMARIN PHARM Stable tablet formulation
Nov, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 13, 2012
Orphan Drug Exclusivity(ODE) Dec 13, 2014
New Patient Population(NPP) Apr 23, 2017
Pediatric Exclusivity(PED) Oct 23, 2017

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

NCE-1 date: 23 October, 2016

Market Authorisation Date: 13 December, 2007

Treatment: NA

Dosage: TABLET; POWDER

More Information on Dosage

KUVAN family patents

Family Patents

122. Kybella patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846066 ABBVIE Methods and related compositions for reduction of fat and skin tightening
Feb, 2025

(a month from now)

US8298556 ABBVIE Methods and related compositions for the non-surgical removal of fat
Aug, 2025

(7 months from now)




Drugs and Companies using DEOXYCHOLIC ACID ingredient

Market Authorisation Date: 29 April, 2015

Treatment: Method for reduction of submental fat

Dosage: SOLUTION

More Information on Dosage

KYBELLA family patents

Family Patents

123. Kyprolis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8207297 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)

US8207125 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)

US7232818 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207127 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)

US8129346 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)

US7491704 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)

US8207126 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2017
New Indication(I-712) Jul 24, 2018
New Indication(I-722) Jan 21, 2019
New Indication(I-723) Jan 21, 2019
Orphan Drug Exclusivity(ODE) Jul 20, 2019
Orphan Drug Exclusivity(ODE-27) Jul 20, 2019
New Dosing Schedule(D-172) Sep 28, 2021
New Indication(I-842) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

NCE-1 date: 20 July, 2016

Market Authorisation Date: 07 June, 2018

Treatment: Kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy

Dosage: POWDER

How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage

KYPROLIS family patents

Family Patents

124. Lantus Solostar patent expiration

LANTUS SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(3 months from now)




Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 27 April, 2007

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LANTUS SOLOSTAR family patents

Family Patents

125. Latuda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound
Dec, 2025

(1 year, 7 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-134) Apr 26, 2015
New Chemical Entity Exclusivity(NCE) Oct 28, 2015
New Indication(I-674) Jun 28, 2016
M(M-195) Jan 27, 2020
Pediatric Exclusivity(PED) Jul 27, 2020
New Patient Population(NPP) Mar 05, 2021

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

NCE-1 date: 28 July, 2019

Market Authorisation Date: 07 December, 2011

Treatment: NA

Dosage: TABLET

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents

126. Lenvima patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-734) May 13, 2019
New Chemical Entity Exclusivity(NCE) Feb 13, 2020
New Indication(I-787) Aug 15, 2021
Orphan Drug Exclusivity(ODE) Feb 13, 2022
Orphan Drug Exclusivity(ODE-87) Feb 13, 2022
New Indication(I-807) Sep 17, 2022
M(M-269) Jul 21, 2024
New Indication(I-868) Aug 10, 2024
M(M-272) Dec 19, 2024
Orphan Drug Exclusivity(ODE-196) Aug 15, 2025
M(M-14) Apr 03, 2027
Pediatric Exclusivity(PED) Oct 03, 2027

Drugs and Companies using LENVATINIB MESYLATE ingredient

NCE-1 date: 03 October, 2026

Market Authorisation Date: 13 February, 2015

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

127. Levemir Flextouch patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LEVEMIR FLEXTOUCH family patents

Family Patents

128. Livdelzi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7301050 GILEAD SCIENCES INC 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
Aug, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 14, 2029
Orphan Drug Exclusivity(ODE-486) Aug 14, 2031

Drugs and Companies using SELADELPAR LYSINE ingredient

NCE-1 date: 14 August, 2028

Market Authorisation Date: 14 August, 2024

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

LIVDELZI family patents

Family Patents

129. Locoid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981877 BAUSCH Stabilized steroid composition and method for its preparation
Jan, 2025

(a month from now)




Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient

Market Authorisation Date: 18 May, 2007

Treatment: NA

Dosage: LOTION

How can I launch a generic of LOCOID before it's drug patent expiration?
More Information on Dosage

LOCOID family patents

Family Patents

130. Lonhala Magnair Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7931212 SUMITOMO PHARMA AM Fluid droplet production apparatus and method
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

131. Lovaza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732488 WOODWARD Pharmaceutical composition comprising low concentrations of environmental pollutants
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-87) Sep 16, 2012

Drugs and Companies using OMEGA-3-ACID ETHYL ESTERS ingredient

Market Authorisation Date: 10 November, 2004

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

LOVAZA family patents

Family Patents

132. Lumigan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309605 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8524777 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8933120 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8278353 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8586630 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8933127 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8299118 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US9241918 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US9155716 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8772338 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)

US8338479 ABBVIE Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 31, 2013

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 31 August, 2010

Treatment: Method of treating glaucoma in a patient; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of reducing intraocular pressure in patients with open a...

Dosage: SOLUTION/DROPS

How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage

LUMIGAN family patents

Family Patents

133. Lupkynis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 22 January, 2025

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE

More Information on Dosage

LUPKYNIS family patents

Family Patents

134. Lybalvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7262298 ALKERMES INC 4-hydroxybenzomorphans
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

LYBALVI family patents

Family Patents

135. Lymphoseek Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6409990 CARDINAL HEALTH 414 Macromolecular carrier for drug and diagnostic agent delivery
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-687) Jun 13, 2017
New Chemical Entity Exclusivity(NCE) Mar 13, 2018
Orphan Drug Exclusivity(ODE) Jun 13, 2021
Orphan Drug Exclusivity(ODE-67) Jun 13, 2021
New Patient Population(NPP) May 19, 2024

Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient

NCE-1 date: 13 March, 2017

Market Authorisation Date: 13 March, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LYMPHOSEEK KIT family patents

Family Patents

136. Lysteda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947739 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US9060939 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US8273795 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US8487005 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US8022106 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US8809394 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US8957113 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)

US8791160 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Nov 13, 2012

Drugs and Companies using TRANEXAMIC ACID ingredient

Market Authorisation Date: 13 November, 2009

Treatment: Treatment of cyclic heavy menstrual bleeding

Dosage: TABLET

More Information on Dosage

LYSTEDA family patents

Family Patents

137. Mekinist patent expiration

Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(5 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...

Dosage: TABLET; SOLUTION

More Information on Dosage

MEKINIST family patents

Family Patents

138. Mektovi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: NA

Dosage: TABLET

More Information on Dosage

MEKTOVI family patents

Family Patents

139. Mirvaso patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis
May, 2025

(5 months from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema
May, 2025

(5 months from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2025

(5 months from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea
Aug, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 23, 2016

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL

More Information on Dosage

MIRVASO family patents

Family Patents

140. Myfembree patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7300935 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Jan, 2025

(a month from now)

US8058280 SUMITOMO PHARMA Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 26, 2024
New Indication(I-898) Aug 05, 2025
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
M(M-289) Jan 27, 2026

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

MYFEMBREE family patents

Family Patents

141. Naloxone Hydrochloride (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(30 days from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(3 months from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(4 months from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents

Family Patents

142. Namenda Xr patent expiration

NAMENDA XR's oppositions filed in EPO
NAMENDA XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168209 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8329752 ABBVIE Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8362085 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8598233 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8173708 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8283379 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 21, 2013
M(M-138) Jul 03, 2017
Pediatric Exclusivity(PED) Jan 03, 2018

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 June, 2010

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of NAMENDA XR before it's drug patent expiration?
More Information on Dosage

NAMENDA XR family patents

Family Patents

143. Namzaric patent expiration

NAMZARIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283379 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(11 months from now)

US8173708 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8580858 ABBVIE Compositions for the treatment of CNS-related conditions
Nov, 2025

(11 months from now)

US8338486 ABBVIE Methods for the treatment of CNS-related conditions
Nov, 2025

(11 months from now)

US8293794 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(11 months from now)

US8362085 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8168209 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8338485 ABBVIE Compositions for the treatment of CNS-related conditions
Nov, 2025

(11 months from now)

US8598233 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)

US8329752 ABBVIE Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(11 months from now)




Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 July, 2016

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage

NAMZARIC family patents

Family Patents

144. Naropin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7828787 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
Oct, 2025

(10 months from now)




Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2011

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of NAROPIN before it's drug patent expiration?
More Information on Dosage

NAROPIN family patents

Family Patents

145. Nerlynx patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982043 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 17, 2022
New Indication(I-823) Feb 25, 2023
New Dosing Schedule(D-182) Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: 17 July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy

Dosage: TABLET

More Information on Dosage

NERLYNX family patents

Family Patents

146. Nesina patent expiration

Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019
M(M-300) Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET

More Information on Dosage

NESINA family patents

Family Patents

147. Neupro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246980 UCB INC Transdermal delivery system
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 09, 2012
New Indication(I-646) Apr 02, 2015
New Indication(I-647) Apr 02, 2015

Drugs and Companies using ROTIGOTINE ingredient

NCE-1 date: 10 May, 2011

Market Authorisation Date: 02 April, 2012

Treatment: NA

Dosage: FILM, EXTENDED RELEASE

More Information on Dosage

NEUPRO family patents

Family Patents

148. Nevanac patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071648 HARROW EYE Topical nepafenac formulations
Dec, 2025

(11 months from now)

US8324281 HARROW EYE Topical nepafenac formulations
Dec, 2025

(11 months from now)




Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 19 August, 2005

Treatment: NA

Dosage: SUSPENSION/DROPS

More Information on Dosage

NEVANAC family patents

Family Patents

149. Nextstellis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 15 April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET

More Information on Dosage

NEXTSTELLIS family patents

Family Patents

150. Norditropin Flexpro patent expiration

NORDITROPIN FLEXPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN RECOMBINANT ingredient

Market Authorisation Date: 23 January, 2015

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

151. Norditropin Flexpro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN ingredient

Market Authorisation Date: 23 January, 2015

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

152. Norvir patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8691878

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)

US8268349

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)

US8399015

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-184) Jun 07, 2024

Drugs and Companies using RITONAVIR ingredient

Market Authorisation Date: 10 February, 2010

Treatment: NA

Dosage: TABLET

More Information on Dosage

NORVIR family patents

Family Patents

153. Novolog Flextouch patent expiration

NOVOLOG FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

NOVOLOG FLEXTOUCH family patents

Family Patents

154. Nucynta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7994364

(Pediatric)

COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Dec, 2025

(1 year, 11 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Patient Population(NPP) Jul 03, 2026
Pediatric Exclusivity(PED) Jan 03, 2027

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 03 January, 2026

Market Authorisation Date: 20 November, 2008

Treatment: Management of moderate to severe acute pain

Dosage: TABLET; SOLUTION

More Information on Dosage

NUCYNTA family patents

Family Patents

155. Nucynta Er patent expiration

NUCYNTA ER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7994364

(Pediatric)

COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Dec, 2025

(1 year, 11 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Dosage Form(NDF) Aug 25, 2014
New Indication(I-656) Aug 28, 2015

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: Management of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents

156. Nulibry patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7504095 SENTYNL THERAPS INC Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-286) Oct 27, 2025
New Chemical Entity Exclusivity(NCE) Feb 26, 2026
Orphan Drug Exclusivity(ODE-342) Feb 26, 2028

Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient

NCE-1 date: 26 February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: Method of treating molybdenum cofactor deficiency type a

Dosage: POWDER

More Information on Dosage

NULIBRY family patents

Family Patents

157. Nuplazid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7923564 ACADIA PHARMS INC Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Sep, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 29, 2021

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

NCE-1 date: 29 April, 2020

Market Authorisation Date: 28 June, 2018

Treatment: NA

Dosage: TABLET; CAPSULE

How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage

NUPLAZID family patents

Family Patents

158. Nuzyra patent expiration

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN) Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: TABLET; POWDER

More Information on Dosage

NUZYRA family patents

Family Patents

159. Odefsey patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 months from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-206) Aug 21, 2020
M(M-207) Aug 21, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET

More Information on Dosage

ODEFSEY family patents

Family Patents

160. Ofev patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Indication(I-805) Sep 06, 2022
New Indication(I-825) Mar 09, 2023
Orphan Drug Exclusivity(ODE-261) Sep 06, 2026
Pediatric Exclusivity(PED) Mar 06, 2027

Drugs and Companies using NINTEDANIB ESYLATE ingredient

NCE-1 date: 06 March, 2026

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

OFEV family patents

Family Patents

161. Ogsiveo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951958 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Mar, 2025

(2 months from now)

US7342118 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(8 months from now)

US7795447 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 27, 2028
ODE*(ODE*) Nov 27, 2030
Orphan Drug Exclusivity(ODE-452) Nov 27, 2030

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

OGSIVEO family patents

Family Patents

162. Olux E patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000 NORVIUM BIOSCIENCE Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 months from now)




Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 12 January, 2007

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM

How can I launch a generic of OLUX E before it's drug patent expiration?
More Information on Dosage

OLUX E family patents

Family Patents

163. Olysio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-697) Nov 05, 2017
New Dosing Schedule(D-151) Oct 05, 2018
New Indication(I-717) Oct 05, 2018
New Chemical Entity Exclusivity(NCE) Nov 22, 2018
M(M-171) Feb 26, 2019
M(M-179) May 20, 2019

Drugs and Companies using SIMEPREVIR SODIUM ingredient

NCE-1 date: 22 November, 2017

Market Authorisation Date: 22 November, 2013

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

OLYSIO family patents

Family Patents

164. Omegaven patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(6 months from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2023
Orphan Drug Exclusivity(ODE-202) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: 27 July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of liver disease through nutrition for patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease

Dosage: EMULSION

More Information on Dosage

OMEGAVEN family patents

Family Patents

165. Omeprazole patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023391 DEXCEL PHARMA Stable benzimidazole formulation
Aug, 2025

(7 months from now)




Drugs and Companies using OMEPRAZOLE ingredient

Market Authorisation Date: 04 December, 2007

Treatment: NA

Dosage: TABLET, DELAYED RELEASE

More Information on Dosage

OMEPRAZOLE family patents

Family Patents

166. Onivyde patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9782349 IPSEN Liposomes useful for drug delivery
May, 2025

(4 months from now)

US10722508 IPSEN Liposomes useful for drug delivery
May, 2025

(4 months from now)

US9724303 IPSEN Liposomes useful for drug delivery
May, 2025

(4 months from now)

US8992970 IPSEN Liposomes useful for drug delivery
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730891 IPSEN Liposomes useful for drug delivery
May, 2025

(4 months from now)

US8703181 IPSEN Liposomes useful for drug delivery
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 22, 2018
Orphan Drug Exclusivity(ODE) Oct 22, 2022
Orphan Drug Exclusivity(ODE-99) Oct 22, 2022
New Indication(I-932) Feb 13, 2027
Orphan Drug Exclusivity(ODE-463) Feb 13, 2031

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer

Dosage: INJECTABLE, LIPOSOMAL

More Information on Dosage

ONIVYDE family patents

Family Patents

167. Onpattro patent expiration

Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023
Orphan Drug Exclusivity(ODE-197) Aug 10, 2025
M(M-270) Jan 13, 2026

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ONPATTRO family patents

Family Patents

168. Onzetra Xsail patent expiration

ONZETRA XSAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7975690 CURRAX Nasal devices
Aug, 2025

(8 months from now)

US8590530 CURRAX Nasal delivery devices
Sep, 2025

(8 months from now)

US9108015 CURRAX Nasal delivery devices
Sep, 2025

(8 months from now)




Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity

Dosage: POWDER

More Information on Dosage

ONZETRA XSAIL family patents

Family Patents

169. Opana Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192722 ENDO PHARMS Abuse-proof dosage form
Sep, 2025

(8 months from now)




Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

OPANA ER family patents

Family Patents

170. Opsumit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 18, 2018
Orphan Drug Exclusivity(ODE) Oct 18, 2020
Orphan Drug Exclusivity(ODE-54) Oct 18, 2020

Drugs and Companies using MACITENTAN ingredient

NCE-1 date: 18 October, 2017

Market Authorisation Date: 18 October, 2013

Treatment: NA

Dosage: TABLET

How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage

OPSUMIT family patents

Family Patents

171. Opsynvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2027
Orphan Drug Exclusivity(ODE-475) Mar 22, 2031

Drugs and Companies using MACITENTAN; TADALAFIL ingredient

Market Authorisation Date: 22 March, 2024

Treatment: NA

Dosage: TABLET

More Information on Dosage

OPSYNVI family patents

Family Patents

172. Oracea patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206740 GALDERMA LABS LP Once daily formulations of tetracyclines
Dec, 2025

(1 year, 8 days from now)




Drugs and Companies using DOXYCYCLINE ingredient

Market Authorisation Date: 26 May, 2006

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE

More Information on Dosage

ORACEA family patents

Family Patents

173. Oraverse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7575757 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 18, 2019

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Market Authorisation Date: 09 May, 2008

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

ORAVERSE family patents

Family Patents

174. Orgovyx patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8058280 SUMITOMO PHARMA Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2025

(a month from now)

US7300935 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: NA

Dosage: TABLET

More Information on Dosage

ORGOVYX family patents

Family Patents

175. Orserdu patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2025

(1 year, 9 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 27 January, 2027

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer

Dosage: TABLET

More Information on Dosage

ORSERDU family patents

Family Patents

176. Oseni patent expiration

Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 25, 2016
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET

More Information on Dosage

OSENI family patents

Family Patents

177. Osmolex Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895615 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8889740 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895614 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8987333 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895616 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8796337 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895617 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US9072697 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8895618 SUPERNUS PHARMS Composition and method for treating neurological disease
Nov, 2025

(11 months from now)

US8574626 SUPERNUS PHARMS Osmotic device containing amantadine and an osmotic salt
Nov, 2025

(11 months from now)




Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of parkinson's disease; Treatment of drug-induced extrapyramidal reaction in adult patients; A ...

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

OSMOLEX ER family patents

Family Patents

178. Osphena patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6245819 DUCHESNAY Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
Jul, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2018
New Indication(I-793) Jan 25, 2022

Drugs and Companies using OSPEMIFENE ingredient

NCE-1 date: 26 February, 2017

Market Authorisation Date: 26 February, 2013

Treatment: Treatment of dyspareunia associated with menopause

Dosage: TABLET

How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage

OSPHENA family patents

Family Patents

179. Oxaydo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7201920 ZYLA Methods and compositions for deterring abuse of opioid containing dosage forms
Mar, 2025

(2 months from now)




Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET

More Information on Dosage

OXAYDO family patents

Family Patents

180. Oxycontin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(3 months from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(3 months from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US12060361 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US7776314 PURDUE PHARMA LP Abuse-proofed dosage system
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-153) Apr 16, 2016
New Patient Population(NPP) Aug 13, 2018

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 December, 1995

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

OXYCONTIN family patents

Family Patents

181. Ozempic patent expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(7 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023
New Dosing Schedule(D-185) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

182. Pexeva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(4 months from now)




Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 03 July, 2003

Treatment: NA

Dosage: TABLET

More Information on Dosage

PEXEVA family patents

Family Patents

183. Pomalyst patent expiration

Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8198262 BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(6 months from now)

US8198262

(Pediatric)

BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Dec, 2025

(1 year, 1 day from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 08, 2018
New Indication(I-707) Apr 23, 2018
Orphan Drug Exclusivity(ODE) Feb 08, 2020
Orphan Drug Exclusivity(ODE-43) Feb 08, 2020
M(M-14) Nov 20, 2023
Orphan Drug Exclusivity(ODE-296) May 14, 2027
Orphan Drug Exclusivity(ODE-297) May 14, 2027
Pediatric Exclusivity(PED) Nov 14, 2027

Drugs and Companies using POMALIDOMIDE ingredient

NCE-1 date: 14 November, 2026

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on o...

Dosage: CAPSULE

How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage

POMALYST family patents

Family Patents

184. Ponvory patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728 VANDA PHARMS INC Thiazolidin-4-one derivatives
Nov, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273779 VANDA PHARMS INC Thiazolidin 4-one derivatives
Dec, 2025

(1 year, 1 day from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET

More Information on Dosage

PONVORY family patents

Family Patents

185. Posimir patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8153661 INNOCOLL Controlled delivery system
Sep, 2025

(8 months from now)

US8846072 INNOCOLL Controlled delivery system
Sep, 2025

(8 months from now)

US8753665 INNOCOLL Controlled delivery system
Sep, 2025

(8 months from now)

US8153149 INNOCOLL Controlled delivery system
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 01, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: Method for providing sustained local anesthesia for at least 24 hours

Dosage: SOLUTION

More Information on Dosage

POSIMIR family patents

Family Patents

186. Pradaxa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 19, 2015
New Indication(I-682) Apr 04, 2017
New Indication(I-683) Apr 04, 2017
M(M-168) Nov 20, 2018
New Strength(NS) Nov 20, 2018
New Indication(I-862) Jun 21, 2024
New Product(NP) Jun 21, 2024
Pediatric Exclusivity(PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Market Authorisation Date: 21 June, 2021

Treatment: NA

Dosage: PELLETS; CAPSULE

More Information on Dosage

PRADAXA family patents

Family Patents

187. Proair Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765820 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US9463288 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

188. Proair Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765820 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)

US9463288 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 12, 2018
New Patient Population(NPP) Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED

More Information on Dosage

PROAIR RESPICLICK family patents

Family Patents

189. Prolensa patent expiration

PROLENSA's oppositions filed in EPO
PROLENSA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129431 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2016

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: NA

Dosage: SOLUTION/DROPS

How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage

PROLENSA family patents

Family Patents

190. Promacta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Indication(I-664) Nov 16, 2015
Orphan Drug Exclusivity(ODE) Nov 20, 2015
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE-75) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
Orphan Drug Exclusivity(ODE-210) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

NCE-1 date: 26 February, 2021

Market Authorisation Date: 20 October, 2011

Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: TABLET

More Information on Dosage

PROMACTA family patents

Family Patents

191. Promacta Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE) Aug 26, 2021
Orphan Drug Exclusivity(ODE-74) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
ODE*(ODE*) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 27 September, 2018

Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION

How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage

PROMACTA KIT family patents

Family Patents

192. Protonix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838027

(Pediatric)

WYETH PHARMS Pantoprazole multiparticulate formulations
Mar, 2025

(3 months from now)

US7553498

(Pediatric)

WYETH PHARMS Pantoprazole multiparticulate formulations
Mar, 2025

(3 months from now)

US7550153

(Pediatric)

WYETH PHARMS Pantoprazole multiparticulate formulations
Mar, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-614) Nov 12, 2012
M(M-54) Nov 12, 2012
Pediatric Exclusivity(PED) May 12, 2013

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Market Authorisation Date: 14 November, 2007

Treatment: NA

Dosage: FOR SUSPENSION, DELAYED RELEASE

More Information on Dosage

PROTONIX family patents

Family Patents

193. Qoliana patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117 SANDOZ Topical brimonidine tartrate formulations that lack chlorine dioxide
Aug, 2025

(8 months from now)




Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SOLUTION/DROPS

More Information on Dosage

QOLIANA family patents

Family Patents

194. Qtern patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-175) Apr 05, 2019
New Combination(NC) Feb 27, 2020
New Indication(I-804) May 02, 2022
New Strength(NS) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET

More Information on Dosage

QTERN family patents

Family Patents

195. Qternmet Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

QTERNMET XR family patents

Family Patents

196. Quartette patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450299 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2016

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 28 March, 2013

Treatment: Prevention of pregnancy

Dosage: TABLET

More Information on Dosage

QUARTETTE family patents

Family Patents

197. Qutenza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10034841 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2014
Orphan Drug Exclusivity(ODE) Nov 16, 2016
New Indication(I-838) Jul 17, 2023

Drugs and Companies using CAPSAICIN ingredient

NCE-1 date: 16 November, 2013

Market Authorisation Date: 16 November, 2009

Treatment: NA

Dosage: PATCH

More Information on Dosage

QUTENZA family patents

Family Patents

198. Renvela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7985418 SANOFI Aliphatic amine polymer salts for tableting
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 12, 2012
New Patient Population(NPP) Nov 25, 2019

Drugs and Companies using SEVELAMER CARBONATE ingredient

Market Authorisation Date: 19 October, 2007

Treatment: NA

Dosage: TABLET

How can I launch a generic of RENVELA before it's drug patent expiration?
More Information on Dosage

RENVELA family patents

Family Patents

199. Rukobia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461333 VIIV HLTHCARE Salts of prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 02, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: 02 July, 2024

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

RUKOBIA family patents

Family Patents

200. Ryanodex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 22, 2021
Orphan Drug Exclusivity(ODE-69) Jul 22, 2021

Drugs and Companies using DANTROLENE SODIUM ingredient

Market Authorisation Date: 22 July, 2014

Treatment: NA

Dosage: FOR SUSPENSION

More Information on Dosage

RYANODEX family patents

Family Patents

201. Rytelo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7494982 GERON Modified oligonucleotides for telomerase inhibition
Dec, 2025

(1 year, 11 days from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-482) Jun 06, 2031

Drugs and Companies using IMETELSTAT SODIUM ingredient

Market Authorisation Date: 06 June, 2024

Treatment: NA

Dosage: POWDER

More Information on Dosage

RYTELO family patents

Family Patents

202. Ryzodeg 70/30 patent expiration

RYZODEG 70/30's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 25 September, 2015

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

RYZODEG 70/30 family patents

Family Patents

203. Sanctura Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7410978 ALLERGAN Once daily dosage forms of trospium
Feb, 2025

(a month from now)




Drugs and Companies using TROSPIUM CHLORIDE ingredient

Market Authorisation Date: 03 August, 2007

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

SANCTURA XR family patents

Family Patents

204. Sancuso patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7608282 CUMBERLAND Transdermal granisetron
Jan, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Sep 12, 2011
NE(NE) Sep 12, 2011

Drugs and Companies using GRANISETRON ingredient

Market Authorisation Date: 12 September, 2008

Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting

Dosage: FILM, EXTENDED RELEASE

How can I launch a generic of SANCUSO before it's drug patent expiration?
More Information on Dosage

SANCUSO family patents

Family Patents

205. Saxenda patent expiration

SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(7 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017
New Patient Population(NPP) Dec 04, 2023

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

206. Scenesse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 08, 2024
Orphan Drug Exclusivity(ODE-270) Oct 08, 2026

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: 09 October, 2023

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT

More Information on Dosage

SCENESSE family patents

Family Patents

207. Signifor patent expiration

Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8299209 RECORDATI RARE Pharmaceutical composition comprising cyclic somatostatin analogues
Dec, 2025

(1 year, 11 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
Orphan Drug Exclusivity(ODE) Dec 14, 2019
Orphan Drug Exclusivity(ODE-34) Dec 14, 2019

Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 14 December, 2012

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SIGNIFOR family patents

Family Patents

208. Soliqua 100/33 patent expiration

SOLIQUA 100/33 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI-AVENTIS US Pen-type injector
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SOLIQUA 100/33 family patents

Family Patents

209. Solodyn patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722650 BAUSCH Extended-release minocycline dosage forms
Jun, 2025

(6 months from now)

US8252776 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(6 months from now)

US8268804 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(6 months from now)

US7790705 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(6 months from now)




Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2006

Treatment: Treatment of acne

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of SOLODYN before it's drug patent expiration?
More Information on Dosage

SOLODYN family patents

Family Patents

210. Spinraza patent expiration

Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266822 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Dec, 2025

(11 months from now)

US8110560 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-226) May 14, 2021
New Chemical Entity Exclusivity(NCE) Dec 23, 2021
Orphan Drug Exclusivity(ODE) Dec 23, 2023
Orphan Drug Exclusivity(ODE-127) Dec 23, 2023

Drugs and Companies using NUSINERSEN SODIUM ingredient

NCE-1 date: 23 December, 2020

Market Authorisation Date: 23 December, 2016

Treatment: Treatment of spinal muscular atrophy; Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna

Dosage: SOLUTION

More Information on Dosage

SPINRAZA family patents

Family Patents

211. Spiriva Respimat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(2 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(5 months from now)

US7896264

(Pediatric)

BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 15, 2018
New Patient Population(NPP) Feb 15, 2020
Pediatric Exclusivity(PED) Aug 15, 2020

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 15 September, 2015

Treatment: NA

Dosage: SPRAY, METERED

How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage

SPIRIVA RESPIMAT family patents

Family Patents

212. Sprycel patent expiration

SPRYCEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(a month from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-120) May 21, 2012
Orphan Drug Exclusivity(ODE) Jun 28, 2013
M(M-94) Oct 28, 2013
New Patient Population(NPP) Nov 09, 2020
New Indication(I-791) Dec 21, 2021
Orphan Drug Exclusivity(ODE-164) Nov 09, 2024
Orphan Drug Exclusivity(ODE-225) Dec 21, 2025
Pediatric Exclusivity(PED) Jun 21, 2026

Drugs and Companies using DASATINIB ingredient

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET

More Information on Dosage

SPRYCEL family patents

Family Patents

213. Spy Agent Green Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421280 NOVADAQ TECH Real time imaging during solid organ transplant
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 21, 2021
New Indication(I-911) Jun 05, 2026

Drugs and Companies using INDOCYANINE GREEN ingredient

Market Authorisation Date: 21 November, 2018

Treatment: Visualization of extrahepatic biliary duct attached to donor organ in patients 12 years and older

Dosage: POWDER

More Information on Dosage

SPY AGENT GREEN KIT family patents

Family Patents

214. Stendra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6656935 METUCHEN PHARMS Aromatic nitrogen-containing 6-membered cyclic compounds
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 27, 2017
New Dosing Schedule(D-140) Sep 17, 2017
M(M-282) Oct 18, 2025

Drugs and Companies using AVANAFIL ingredient

NCE-1 date: 27 April, 2016

Market Authorisation Date: 27 April, 2012

Treatment: Treatment of erectile dysfunction

Dosage: TABLET

How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage

STENDRA family patents

Family Patents

215. Stiolto Respimat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(2 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(4 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 21, 2018
M(M-173) Mar 18, 2019
New Chemical Entity Exclusivity(NCE) Jul 31, 2019
M(M-233) Oct 05, 2021

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

NCE-1 date: 31 July, 2018

Market Authorisation Date: 21 May, 2015

Treatment: Treatment of copd; Treatment of respiratory complaints

Dosage: SPRAY, METERED

More Information on Dosage

STIOLTO RESPIMAT family patents

Family Patents

216. Striverdi Respimat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(4 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2019

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2018

Market Authorisation Date: 31 July, 2014

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED

More Information on Dosage

STRIVERDI RESPIMAT family patents

Family Patents

217. Sumavel Dosepro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241243 ENDO OPERATIONS Needleless injector drug capsule and a method for filling thereof
Dec, 2025

(1 year, 9 days from now)




Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 26 November, 2013

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

SUMAVEL DOSEPRO family patents

Family Patents

218. Symbicort patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8875699

(Pediatric)

ASTRAZENECA Inhaler cap strap
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-582) Feb 27, 2012
New Patient Population(NPP) Jan 27, 2020
Pediatric Exclusivity(PED) Jul 27, 2020
M(M-210) Sep 11, 2020
M(M-214) Dec 20, 2020

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient

Market Authorisation Date: 21 July, 2006

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage

SYMBICORT family patents

Family Patents

219. Symdeko (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 21, 2022
New Chemical Entity Exclusivity(NCE) Feb 12, 2023
Orphan Drug Exclusivity(ODE-173) Feb 12, 2025
Orphan Drug Exclusivity(ODE-247) Jun 21, 2026
Orphan Drug Exclusivity(ODE-335) Dec 21, 2027

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Tezacaftor and ivacaftor for the treatment of patients with a mild to moderate clinical phenotype of cystic fibrosis having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor b...

Dosage: TABLET

More Information on Dosage

SYMDEKO (COPACKAGED) family patents

Family Patents

220. Symtuza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 JANSSEN PRODS Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Combination(NC) Jul 17, 2021

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 17 July, 2018

Treatment: NA

Dosage: TABLET

More Information on Dosage

SYMTUZA family patents

Family Patents

221. Tafinlar patent expiration

Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(5 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-47) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-58) Jan 09, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-147) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-894) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 16 March, 2023

Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...

Dosage: TABLET, FOR SUSPENSION; CAPSULE

More Information on Dosage

TAFINLAR family patents

Family Patents

222. Targiniq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(3 months from now)

US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(3 months from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2017

Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2014

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

TARGINIQ family patents

Family Patents

223. Technivie patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)

US8399015

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-743) Jul 24, 2018
New Product(NP) Jul 24, 2018
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

TECHNIVIE family patents

Family Patents

224. Tegsedi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2023
Orphan Drug Exclusivity(ODE-212) Oct 05, 2025

Drugs and Companies using INOTERSEN SODIUM ingredient

NCE-1 date: 05 October, 2022

Market Authorisation Date: 05 October, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TEGSEDI family patents

Family Patents

225. Testim patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320968 ENDO OPERATIONS Pharmaceutical composition
Jan, 2025

(a month from now)




Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 31 October, 2002

Treatment: Method for administration of testosterone

Dosage: GEL

More Information on Dosage

TESTIM family patents

Family Patents

226. Tobi Podhaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664187 MYLAN SPECIALITY LP Methods of treatment of endobronchial infections
Jun, 2025

(6 months from now)

US7559325 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2016

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER

More Information on Dosage

TOBI PODHALER family patents

Family Patents

227. Toujeo Max Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI US SERVICES Pen-type injector
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Nov 26, 2022

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TOUJEO MAX SOLOSTAR family patents

Family Patents

228. Toujeo Solostar patent expiration

TOUJEO SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI US SERVICES Pen-type injector
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 25, 2018
New Patient Population(NPP) Nov 26, 2022

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TOUJEO SOLOSTAR family patents

Family Patents

229. Tradjenta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-118) Aug 13, 2015
M(M-121) Aug 13, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Treatment: NA

Dosage: TABLET

How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage

TRADJENTA family patents

Family Patents

230. Trelegy Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(4 months from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(4 months from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(7 months from now)

US7439393

(Pediatric)

GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
New Indication(I-775) Apr 24, 2021
New Indication(I-843) Sep 09, 2023
New Strength(NS) Sep 09, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 September, 2017

Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via top...

Dosage: POWDER

More Information on Dosage

TRELEGY ELLIPTA family patents

Family Patents

231. Tresiba patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TRESIBA family patents

Family Patents

232. Treximet patent expiration

TREXIMET IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183 CURRAX Multilayer dosage forms containing NSAIDs and triptans
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 14, 2018
Pediatric Exclusivity(PED) Nov 14, 2018

Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 14 May, 2015

Treatment: Treatment of migraine

Dosage: TABLET

More Information on Dosage

TREXIMET family patents

Family Patents

233. Tri-luma patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7939516 GALDERMA LABS LP Topical skin care composition
May, 2025

(4 months from now)




Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient

Market Authorisation Date: 18 January, 2002

Treatment: NA

Dosage: CREAM

More Information on Dosage

TRI-LUMA family patents

Family Patents

234. Trijardy Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(11 months from now)




Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage

TRIJARDY XR family patents

Family Patents

235. Trikafta (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 08, 2024
New Chemical Entity Exclusivity(NCE) Oct 21, 2024
New Product(NP) Apr 26, 2026
Orphan Drug Exclusivity(ODE-275) Oct 21, 2026
Orphan Drug Exclusivity(ODE-323) Dec 21, 2027
Orphan Drug Exclusivity(ODE-357) Jun 08, 2028
Orphan Drug Exclusivity(ODE-433) Apr 26, 2030

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 08 June, 2021

Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 2 to <6 years who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based ...

Dosage: TABLET; GRANULES

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

Family Patents

236. Trilipix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7259186 ABBVIE Salts of fenofibric acid and pharmaceutical formulations thereof
Jan, 2025

(22 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 15, 2011

Drugs and Companies using CHOLINE FENOFIBRATE ingredient

Market Authorisation Date: 15 December, 2008

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE

More Information on Dosage

TRILIPIX family patents

Family Patents

237. Troxyca Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods
Jul, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 19, 2019

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

TROXYCA ER family patents

Family Patents

238. Truqap patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006430 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein
Oct, 2025

(10 months from now)

US8809336 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2028

Drugs and Companies using CAPIVASERTIB ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2023

Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...

Dosage: TABLET

More Information on Dosage

TRUQAP family patents

Family Patents

239. Tudorza Pressair patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46417 COVIS Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2017
M(M-256) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE ingredient

NCE-1 date: 23 July, 2016

Market Authorisation Date: 23 July, 2012

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED

More Information on Dosage

TUDORZA PRESSAIR family patents

Family Patents

240. Twinject 0.15 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136 IMPAX Medicine injection devices and methods
Jan, 2025

(a month from now)

US7621891 IMPAX Method and apparatus for delivering epinephrine
Feb, 2025

(a month from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

TWINJECT 0.15 family patents

Family Patents

241. Twinject 0.3 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136 IMPAX Medicine injection devices and methods
Jan, 2025

(a month from now)

US7621891 IMPAX Method and apparatus for delivering epinephrine
Feb, 2025

(a month from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

TWINJECT 0.3 family patents

Family Patents

242. Tyvaso Dpi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2025

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

TYVASO DPI family patents

Family Patents

243. Utibron patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Product(NP) Oct 29, 2018

Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER

More Information on Dosage

UTIBRON family patents

Family Patents

244. Uzedy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925268 TEVA Drug-containing implants and methods of use thereof
Jan, 2025

(27 days from now)

US9439905 TEVA Risperidone-containing implants and methods of use thereof
Jan, 2025

(27 days from now)

US10736965 TEVA Risperidone biodegradable implant
Jan, 2025

(27 days from now)

US9717799 TEVA Drug-containing implants and methods of use thereof
Jan, 2025

(27 days from now)

US9895447 TEVA Drug-containing PLA implants and methods of use thereof
Jan, 2025

(27 days from now)

US8802127 TEVA Risperidone-containing PLA:PGA implants and methods of use thereof
Jan, 2025

(27 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 28, 2026

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 28 April, 2023

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

UZEDY family patents

Family Patents

245. Valtoco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265402 NEURELIS INC Absorption enhancers for drug administration
May, 2025

(4 months from now)

US9642913 NEURELIS INC Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
May, 2025

(4 months from now)

US8927497 NEURELIS INC Absorption enhancers for intranasal administration
Jul, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 10, 2023
Orphan Drug Exclusivity(ODE-279) Jan 10, 2027

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older

Dosage: SPRAY

More Information on Dosage

VALTOCO family patents

Family Patents

246. Veltassa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7556799 VIFOR PHARMA Ion binding polymers and uses thereof
Feb, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 21, 2020
New Patient Population(NPP) Oct 02, 2026
New Strength(NS) Oct 02, 2026

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

NCE-1 date: 22 October, 2019

Market Authorisation Date: 02 October, 2023

Treatment: Treatment of hyperkalemia

Dosage: POWDER

How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage

VELTASSA family patents

Family Patents

247. Veltin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 months from now)




Drugs and Companies using CLINDAMYCIN PHOSPHATE; TRETINOIN ingredient

Market Authorisation Date: 16 July, 2010

Treatment: Treatment of atopic dermatitis

Dosage: GEL

More Information on Dosage

VELTIN family patents

Family Patents

248. Vemlidy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 11, 2019
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-255) Feb 04, 2023
M(M-266) Aug 22, 2023
New Patient Population(NPP) Oct 17, 2025

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 10 November, 2016

Treatment: NA

Dosage: TABLET

More Information on Dosage

VEMLIDY family patents

Family Patents

249. Ventolin Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXOSMITHKLINE Actuation indicator for a dispensing device
Jan, 2025

(19 days from now)

US7500444

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Jul, 2025

(6 months from now)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 19 April, 2001

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

VENTOLIN HFA family patents

Family Patents

250. Veramyst patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147461 GLAXOSMITHKLINE Fluid dispensing device
Mar, 2025

(2 months from now)




Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 27 April, 2007

Treatment: NA

Dosage: SPRAY, METERED

More Information on Dosage

VERAMYST family patents

Family Patents

251. Verdeso patent expiration

VERDESO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 months from now)

US8962000 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 months from now)




Drugs and Companies using DESONIDE ingredient

Market Authorisation Date: 19 September, 2006

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM

More Information on Dosage

VERDESO family patents

Family Patents

252. Veregen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770406 ANI PHARMS Medicament for the treatment of viral skin and tumour diseases
Jul, 2025

(6 months from now)




Drugs and Companies using SINECATECHINS ingredient

Market Authorisation Date: 31 October, 2006

Treatment: Treatment of genital warts

Dosage: OINTMENT

More Information on Dosage

VEREGEN family patents

Family Patents

253. Viberzi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10213415 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)

US7786158 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)

US8609709 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205076 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)

US8344011 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)

US8772325 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)

US9700542 ABBVIE Compounds as opioid receptor modulators
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2020

Drugs and Companies using ELUXADOLINE ingredient

NCE-1 date: 28 May, 2019

Market Authorisation Date: 27 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)

Dosage: TABLET

More Information on Dosage

VIBERZI family patents

Family Patents

254. Victoza patent expiration

VICTOZA's oppositions filed in EPO
VICTOZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
M(M-115) Apr 06, 2015
M(M-176) Apr 22, 2019
New Indication(I-750) Aug 25, 2020
New Patient Population(NPP) Jun 17, 2022
Pediatric Exclusivity(PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

255. Vizamyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7270800 GE HEALTHCARE Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Sep, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 25, 2018

Drugs and Companies using FLUTEMETAMOL F-18 ingredient

NCE-1 date: 25 October, 2017

Market Authorisation Date: 25 October, 2013

Treatment: Diagnostic radioimaging

Dosage: INJECTABLE

More Information on Dosage

VIZAMYL family patents

Family Patents

256. Vizimpro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 27, 2023
Orphan Drug Exclusivity(ODE-206) Sep 27, 2025
Orphan Drug Exclusivity(ODE-213) Sep 27, 2025

Drugs and Companies using DACOMITINIB ingredient

NCE-1 date: 27 September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test

Dosage: TABLET

More Information on Dosage

VIZIMPRO family patents

Family Patents

257. Vyleesi (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6794489 COSETTE Compositions and methods for treatment of sexual dysfunction
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: 22 June, 2023

Market Authorisation Date: 21 June, 2019

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VYLEESI (AUTOINJECTOR) family patents

Family Patents

258. Vyndamax patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2025

(1 year, 3 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2025

(1 year, 3 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 03, 2024
Orphan Drug Exclusivity(ODE-237) May 03, 2026

Drugs and Companies using TAFAMIDIS ingredient

NCE-1 date: 04 May, 2023

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE

How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage

VYNDAMAX family patents

Family Patents

259. Vyndaqel patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2025

(1 year, 3 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2025

(1 year, 3 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 03, 2024
Orphan Drug Exclusivity(ODE-237) May 03, 2026

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

NCE-1 date: 04 May, 2023

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE

More Information on Dosage

VYNDAQEL family patents

Family Patents

260. Vyondys 53 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(6 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2024
Orphan Drug Exclusivity(ODE-280) Dec 12, 2026

Drugs and Companies using GOLODIRSEN ingredient

NCE-1 date: 13 December, 2023

Market Authorisation Date: 12 December, 2019

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION

More Information on Dosage

VYONDYS 53 family patents

Family Patents

261. Vyxeos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431806 CELATOR PHARMS Liposomal formulations of anthracycline agents and cytidine analogs
Apr, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 03, 2020
New Patient Population(NPP) Mar 30, 2024
Orphan Drug Exclusivity(ODE-287) Aug 03, 2024
Orphan Drug Exclusivity(ODE-350) Mar 30, 2028

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Market Authorisation Date: 03 August, 2017

Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older

Dosage: POWDER

More Information on Dosage

VYXEOS family patents

Family Patents

262. Vyzulta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7910767 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(20 days from now)

US7273946 BAUSCH AND LOMB Prostaglandin derivatives
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(20 days from now)




Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS

More Information on Dosage

VYZULTA family patents

Family Patents

263. Wainua (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8101743 ASTRAZENECA AB Modulation of transthyretin expression
Apr, 2025

(3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2028
Orphan Drug Exclusivity(ODE-461) Dec 21, 2030

Drugs and Companies using EPLONTERSEN SODIUM ingredient

NCE-1 date: 22 December, 2027

Market Authorisation Date: 21 December, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

WAINUA (AUTOINJECTOR) family patents

Family Patents

264. Winlevi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents
Jan, 2025

(27 days from now)

US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
May, 2025

(5 months from now)

US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 26 August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate

Dosage: CREAM

More Information on Dosage

WINLEVI family patents

Family Patents

265. Xalkori patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(2 months from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 26, 2016
Orphan Drug Exclusivity(ODE) Aug 26, 2018
Orphan Drug Exclusivity(ODE-15) Aug 26, 2018
M(M-163) Sep 14, 2018
Orphan Drug Exclusivity(ODE-111) Mar 11, 2023
New Indication(I-852) Jan 14, 2024
New Indication(I-897) Jul 14, 2025
Orphan Drug Exclusivity(ODE-328) Jan 14, 2028
Orphan Drug Exclusivity(ODE-407) Jul 14, 2029

Drugs and Companies using CRIZOTINIB ingredient

Market Authorisation Date: 07 September, 2023

Treatment: NA

Dosage: CAPSULE, PELLETS; CAPSULE

More Information on Dosage

XALKORI family patents

Family Patents

266. Xarelto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(2 months from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-643) Nov 04, 2014
New Indication(I-660) Nov 02, 2015
New Indication(I-661) Nov 02, 2015
New Indication(I-662) Nov 02, 2015
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Dosing Schedule(D-168) Oct 27, 2020
New Indication(I-824) Oct 11, 2021
New Indication(I-810) Oct 11, 2022
M(M-284) Mar 10, 2023
New Indication(I-867) Aug 23, 2024
New Product(NP) Dec 20, 2024
Pediatric Exclusivity(PED) Jun 20, 2025

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date: 24 February, 2024

Market Authorisation Date: 11 October, 2018

Treatment: NA

Dosage: TABLET; FOR SUSPENSION

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

267. Xeljanz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-135) Feb 21, 2017
New Chemical Entity Exclusivity(NCE) Nov 06, 2017
New Indication(I-761) Dec 14, 2020
New Indication(I-780) May 30, 2021
New Product(NP) Sep 25, 2023
New Patient Population(NPP) Sep 25, 2023
New Indication(I-879) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 06 November, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents

268. Xeljanz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-135) Feb 21, 2017
New Chemical Entity Exclusivity(NCE) Nov 06, 2017
New Indication(I-761) Dec 14, 2020
New Indication(I-780) May 30, 2021
New Product(NP) Sep 25, 2023
New Patient Population(NPP) Sep 25, 2023
New Indication(I-879) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 25 September, 2020

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

XELJANZ family patents

Family Patents

269. Xeljanz Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 06, 2017
New Indication(I-761) Dec 14, 2020
New Indication(I-879) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 23 February, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

XELJANZ XR family patents

Family Patents

270. Xelstrym patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8591941 NOVEN PHARMS INC Transdermal drug delivery device including an occlusive backing
Oct, 2025

(9 months from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(9 months from now)

US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: NA

Dosage: SYSTEM

More Information on Dosage

XELSTRYM family patents

Family Patents

271. Xhance patent expiration

XHANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7975690 OPTINOSE US INC Nasal devices
Dec, 2025

(1 year, 13 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 18, 2020
New Indication(I-940) Mar 15, 2027

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED

More Information on Dosage

XHANCE family patents

Family Patents

272. Xifaxan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7906542 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2025

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7915275 SALIX PHARMS Use of polymorphic forms of rifaximin for medical preparations
Feb, 2025

(2 months from now)

US7906542 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 24, 2013
Orphan Drug Exclusivity(ODE) Mar 24, 2017
New Indication(I-709) May 27, 2018

Drugs and Companies using RIFAXIMIN ingredient

Market Authorisation Date: 24 March, 2010

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.

Dosage: TABLET

How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage

XIFAXAN family patents

Family Patents

273. Xigduo Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 28 July, 2017

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

XIGDUO XR family patents

Family Patents

274. Xiidra patent expiration

Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7314938 BAUSCH AND LOMB INC Modulators of cellular adhesion
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 11, 2021

Drugs and Companies using LIFITEGRAST ingredient

NCE-1 date: 11 July, 2020

Market Authorisation Date: 11 July, 2016

Treatment: NA

Dosage: SOLUTION/DROPS

More Information on Dosage

XIIDRA family patents

Family Patents

275. Ximino patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252776 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(6 months from now)

US8268804 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(6 months from now)

US7790705 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(6 months from now)




Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 July, 2012

Treatment: Treatment of acne

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

XIMINO family patents

Family Patents

276. Xtampza Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557291 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Mar, 2025

(3 months from now)

US7771707 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(3 months from now)

US8449909 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(3 months from now)

US7399488 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Mar, 2025

(3 months from now)

US8758813 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jun, 2025

(5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 26, 2019

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

XTAMPZA ER family patents

Family Patents

277. Xultophy 100/3.6 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020
M(M-242) Aug 08, 2022

Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

XULTOPHY 100/3.6 family patents

Family Patents

278. Yupelri patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585879 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US7910608 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10106503 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US7491736 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US7521041 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US7550595 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US11247969 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US8273894 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US10343995 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US8034946 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)

US8053448 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 09, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: 09 November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION

How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage

YUPELRI family patents

Family Patents

279. Zetia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612058 ORGANON Methods for inhibiting sterol absorption
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Dec 05, 2011
M(M-109) Jan 24, 2015

Drugs and Companies using EZETIMIBE ingredient

Market Authorisation Date: 25 October, 2002

Treatment: Reduction of elevated plasma sterol and/or stanol levels in a mammal

Dosage: TABLET

How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage

ZETIA family patents

Family Patents

280. Zokinvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838531 SENTYNL THERAPS INC Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2025

(7 months from now)

US8828356 SENTYNL THERAPS INC Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2025

(10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2025
Orphan Drug Exclusivity(ODE-324) Nov 20, 2027

Drugs and Companies using LONAFARNIB ingredient

NCE-1 date: 20 November, 2024

Market Authorisation Date: 20 November, 2020

Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)

Dosage: CAPSULE

More Information on Dosage

ZOKINVY family patents

Family Patents

281. Zolinza patent expiration

Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7399787 MSD SUB MERCK Methods of treating cancer with HDAC inhibitors
Feb, 2025

(a month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2011
Orphan Drug Exclusivity(ODE) Oct 06, 2013

Drugs and Companies using VORINOSTAT ingredient

NCE-1 date: 06 October, 2010

Market Authorisation Date: 06 October, 2006

Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)

Dosage: CAPSULE

More Information on Dosage

ZOLINZA family patents

Family Patents

282. Zometa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
May, 2025

(5 months from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Nov, 2025

(11 months from now)




Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Sep 20, 2011

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 20 August, 2001

Treatment: Hypercalcemia of malignancy

Dosage: INJECTABLE

How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage

ZOMETA family patents

Family Patents

283. Zuragard patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9011897 ZUREX PHARMA Catheter lock solution comprising citrate and a paraben
Feb, 2025

(a month from now)

US8226971 ZUREX PHARMA Catheter lock solution comprising citrate and a paraben
May, 2025

(4 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 26, 2022
M(M-268) Jun 24, 2024

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 26 April, 2019

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ZURAGARD family patents

Family Patents

284. Zurampic patent expiration

Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2020

Drugs and Companies using LESINURAD ingredient

NCE-1 date: 23 December, 2019

Market Authorisation Date: 22 December, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

ZURAMPIC family patents

Family Patents

285. Zydelig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44638 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Aug, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149477 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
May, 2025

(4 months from now)

US8980901 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
May, 2025

(4 months from now)

USRE44599 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Jul, 2025

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2019
Orphan Drug Exclusivity(ODE) Jul 23, 2021
Orphan Drug Exclusivity(ODE-70) Jul 23, 2021
Orphan Drug Exclusivity(ODE-71) Jul 23, 2021

Drugs and Companies using IDELALISIB ingredient

NCE-1 date: 23 July, 2018

Market Authorisation Date: 23 July, 2014

Treatment: Inhibition on pi3k kinase; For the treatment of patients with cll, fl, or sll

Dosage: TABLET

How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage

ZYDELIG family patents

Family Patents

List of large molecules

1. List of Prolia And Xgeva large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7364736 AMGEN INC. Antibodies to OPGL
Feb, 2025

(2 months from now)

US7427659 AMGEN INC. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
Mar, 2025

(2 months from now)

Ingredients: DENOSUMAB

2. List of Avastin large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7485704 GENENTECH, INC. Reducing protein A leaching during protein A affinity chromatography
Mar, 2025

(2 months from now)

Ingredients: BEVACIZUMAB

3. List of Actemra large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US8734800 GENENTECH, INC. Subtypes of humanized antibody against interleukin-6 receptor
Mar, 2025

(3 months from now)

US9902777 GENENTECH, INC. Methods for producing subtypes of humanized antibody against interleukin-6 receptor
May, 2025

(5 months from now)

Ingredients: TOCILIZUMAB

4. List of Humira large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US8986693 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriasis
Apr, 2025

(3 months from now)

US8961973 ABBVIE INC. Multiple-variable dose regimen for treating TNFα-related disorders
Apr, 2025

(3 months from now)

US8961974 ABBVIE INC. Multiple-variable dose regimen for treating TNFα-related disorders
Apr, 2025

(3 months from now)

US9512216 ABBVIE INC. Use of TNFα inhibitor
Apr, 2025

(3 months from now)

US9061005 ABBVIE INC. Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Apr, 2025

(3 months from now)

US9187559 ABBVIE INC. Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Apr, 2025

(3 months from now)

Ingredients: ADALIMUMAB

5. List of Rituxan large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7976838 GENENTECH, INC. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor
Jun, 2025

(6 months from now)

Ingredients: RITUXIMAB

6. List of Xolair large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10034940 GENENTECH, INC. High concentration antibody and protein formulations
Nov, 2025

(10 months from now)

Ingredients: OMALIZUMAB